COVID-19 E protein biochemical studies

NIH Pandemic-Era Grants

Pandemic Era Grants

2021

↗ Live URL (may be dead)

Document text

Principal Investigator: SANJAY A DESAI
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $50,010
Funding agency: National Institute of Allergy and Infectious Diseases

This is a new project undertaken this year based on identified knowledge gaps in the roles served by E protein in coronavirus infections.  Because our laboratory has the required technologies, we have initiated the following specific aims within this project.
  
AIM 1: Use electrophysiology to determine essential transport properties of SARS-CoV-2 E protein. We are using recombinant E protein in electrophysiology experiments to define the essential transport properties of this protein encoded by the SARS-CoV-2 coronavirus.  Our experiments are designed to directly establish whether purified E protein can form ion channels, to use single-channel studies to measure ion flux rates and the pores preference for specific ions.  These selectivity measurements are essential for defining the role and mechanism of viroporin action in SARS-CoV-2 replication and disease pathogenesis. 

AIM 2: Develop and miniaturize a mammalian cell-based, target-specific reporter assay for viroporin activity. We are developing a cell-based assay for E protein activity suitable for measurements in individual wells of a 384-well microplate. 

AIM 3: Execute a high-throughput screen for small molecule inhibitors. A chemical screen will be executed using the above cell-based assay to find potent inhibitors of the E protein channel. 

AIM 4: Evaluate inhibitor-mediated block of viral replication in cultured mammalian cells via the NIAID SARS-CoV-2 virology core (SVC). As inhibitors are identified, we will collaborate with the SARS-CoV-2 Virology Core (SVC) for BSL-3 studies to evaluate in vitro and in vivo inhibition of viral replication by viroporin inhibitors. These studies will guide the selection of compounds for advancement into hit-to-lead chemistry and the antiviral drug development pipeline.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Animals><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Bioassay><Biochemical><Biologic Assays><Biological Assay><COVID-19><COVID-19 therapy><COVID-19 treatment><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 therapy><COVID19 treatment><COVID19 virus><CV-19><CV19><Cell Body><Cells><Chemicals><Chemistry><CoV-2><CoV2><Coronaviridae><Coronaviridae Infections><Coronavirus><Coronavirus Infections><Disease><Disease Outbreaks><Disorder><E protein><Electrophysiology><Electrophysiology (science)><Future><Goals><High Throughput Assay><In Vitro><Individual><Ion Channel><Ionic Channels><Ions><Knowledge><Laboratories><Lead><Mammalian Cell><Measurement><Measures><Mediating><Membrane Channels><NIAID><National Institute of Allergy and Infectious Disease><Neurophysiology / Electrophysiology><Outbreaks><Pathogenesis><Patients><Pb element><Property><Proteins><Recombinants><Reporter><Role><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scaffolding Protein><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Technology><Virus><Virus Replication><Virus-like particle><Wuhan coronavirus><anti-viral agents><anti-viral drugs><anti-virals><base><chemotherapy><corona virus><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><design><designing><drug development><electrophysiological><experiment><experimental research><experimental study><hCoV19><heavy metal Pb><heavy metal lead><high throughput screening><in vivo><inhibitor><inhibitor/antagonist><miniaturize><nCoV2><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel therapeutics><novel therapy><preference><reconstitute><reconstitution><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><small molecule inhibitor><social role><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><viral multiplication><viral replication><virology><virus multiplication><virus-like nanoparticles><viruslike particle>